A Study of Ragweed (Ambrosia Artemisiifolia) Allergy Immunotherapy Tablet in Adults With Ragweed Allergies (P05751)

Exclusion Criteria

• •Unstable asthma or has experienced an occurrence of any clinical deterioration of asthma that resulted in emergency treatment, hospitalization due to asthma, or treatment with systemic corticosteroids in previous 3 months
• •Received an immunosuppressive treatment within 3 months
• •History of anaphylaxis with cardio-respiratory symptoms.
• •History of chronic urticaria or angioedema
• •Current severe atopic dermatitis
• •Female subject who is breastfeeding, pregnant, or intending to become pregnant
• •Has received maintenance doses of immunotherapy with ragweed extract for ≥1 month within the last 5 years
• •History of allergy, hypersensitivity or intolerance to the ingredients of the investigational medicinal products (IMPs) (except for Ambrosia artemisiifolia), or self-injectable epinephrine
• •Unable to or will not comply with the use of self-injectable epinephrine
• •Participating in any other clinical trial